Amedisys Stock Net Income
| AMED Stock | USD 90.16 0.16 0.18% |
Amedisys fundamentals help investors to digest information that contributes to Amedisys' financial success or failures. It also enables traders to predict the movement of Amedisys Stock. The fundamental analysis module provides a way to measure Amedisys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amedisys stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -9.7 M | -9.3 M | |
| Net Income Applicable To Common Shares | 136.4 M | 143.2 M | |
| Net Income From Continuing Ops | 1.6 M | 1.5 M | |
| Net Loss | (0.30) | (0.28) | |
| Net Loss | (0.25) | (0.23) |
Amedisys | Net Income |
Amedisys Company Net Income Analysis
Amedisys' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Amedisys Net Income | (9.75 M) |
Most of Amedisys' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amedisys is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Amedisys Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Amedisys is extremely important. It helps to project a fair market value of Amedisys Stock properly, considering its historical fundamentals such as Net Income. Since Amedisys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amedisys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amedisys' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Amedisys Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Amedisys reported net income of (9.75 Million). This is 102.86% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 101.71% higher than that of the company.
Amedisys Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amedisys' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amedisys could also be used in its relative valuation, which is a method of valuing Amedisys by comparing valuation metrics of similar companies.Amedisys is currently under evaluation in net income category among its peers.
Amedisys ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amedisys' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amedisys' managers, analysts, and investors.Environmental | Governance | Social |
Amedisys Institutional Holders
Institutional Holdings refers to the ownership stake in Amedisys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amedisys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amedisys' value.| Shares | Mackenzie Investments | 2024-09-30 | 694.6 K | Magnetar Financial Llc | 2024-06-30 | 615.5 K | Geode Capital Management, Llc | 2024-06-30 | 560 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 509.3 K | Cresset Asset Management, Llc | 2024-06-30 | 455.9 K | Sand Grove Capital Management Llp | 2024-06-30 | 435.1 K | Qube Research & Technologies | 2024-06-30 | 412.3 K | Cnh Partners, Llc | 2024-06-30 | 400.4 K | Calamos Advisors Llc | 2024-06-30 | 397.3 K | Vanguard Group Inc | 2024-09-30 | 3.2 M | Blackrock Inc | 2024-06-30 | 3.1 M |
Amedisys Fundamentals
| Return On Equity | 0.0721 | ||||
| Return On Asset | 0.0627 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 3.17 B | ||||
| Shares Outstanding | 32.75 M | ||||
| Shares Owned By Insiders | 2.37 % | ||||
| Shares Owned By Institutions | 90.30 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 2.57 X | ||||
| Price To Sales | 1.27 X | ||||
| Revenue | 2.24 B | ||||
| Gross Profit | 453.98 M | ||||
| EBITDA | 216.91 M | ||||
| Net Income | (9.75 M) | ||||
| Cash And Equivalents | 17.96 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 487.21 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 35.05 X | ||||
| Cash Flow From Operations | 137.19 M | ||||
| Short Ratio | 5.97 X | ||||
| Earnings Per Share | 2.52 X | ||||
| Price To Earnings To Growth | 1.30 X | ||||
| Target Price | 96.33 | ||||
| Number Of Employees | 19 K | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 2.95 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | 747.92 M | ||||
| Working Capital | 23.21 M | ||||
| Current Asset | 175.26 M | ||||
| Current Liabilities | 175.19 M | ||||
| Net Asset | 2.06 B |
About Amedisys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amedisys's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amedisys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amedisys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Amedisys Piotroski F Score and Amedisys Altman Z Score analysis. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.35) | Earnings Share 2.52 | Revenue Per Share 71.004 | Quarterly Revenue Growth 0.057 | Return On Assets 0.0627 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.